HIV triple therapy tablet containing new version of tenofovir

Odefsey (rilpivirine/emtricitabine/tenofovir alafenamide) is indicated in the treatment of patients aged 12 years and over and weighing at least 35kg who are infected with HIV-1 without known mutations associated with resistance to NNRTIs, tenofovir or emtricitabine and who have a viral load ≤100,000 HIV-1 RNA copies/ml. The 25mg/200mg/25mg tablet should be taken once daily with food.

Further information
View Odefsey drug record
Summary of Product Characteristics
Manufacturer: Gilead Sciences

Gilead also markets Eviplera, a similar product containing rilpivirine 25mg and emtricitabine 200mg but with a different tenofovir salt (tenofovir disoproxil 245mg).

Tenofovir alafenamide is a novel targeted prodrug of tenofovir which has high antiviral efficacy similar to tenofovir disoproxil but at a significantly lower dose (25mg versus 245mg).

As a result, Odefsey may be used in patients with moderate renal impairment (CrCl ≥30ml/min) while Eviplera is contraindicated if creatinine clearance is below 50ml/min. In addition, Eviplera is associated with a risk of reduced bone mineral density, especially when used in combination with a boosted protease inhibitor and alternative regimens should be considered in patients with osteoporosis and a high fracture risk. No such warning applies to the use of Odefsey.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more